Showing 5581-5590 of 9788 results for "".
- EltaMD Teams Up With Bravo's Andy Cohen for Skin Cancer Awarenesshttps://practicaldermatology.com/news/eltamd-teams-up-with-bravos-andy-cohen-for-skin-cancer-awareness/2461729/EltaMD has partnered with Andy Cohen and the Melanoma Research Foundation on a social campaign aimed to ignite dialogue surrounding skin cancer, while educating consumers on the importance of skin checks for National Skin Cancer Awareness Month. As part of this initiative, and to encour
- Study: Spironolactone May Be an Alternative to Antibiotics for Women With Persistent Acnehttps://practicaldermatology.com/news/study-spironolactone-may-be-an-alternative-to-antibiotics-for-women-with-persistent-acne/2461725/Spironolactone could be a cheap and readily available alternative to antibiotics for women with persistent acne, according to research out of the University of Southampton. The results of the trial appear in the Bri
- Dr. David Simon Wins Pershing Square Sohn Prize for Young Investigators in Cancer Research to Study Melanomahttps://practicaldermatology.com/news/dr-david-simon-wins-pershing-square-sohn-prize-for-young-investigators-in-cancer-research-to-studying-melanoma/2461722/Dr. David Simon has won the Pershing Square Sohn Prize for Young Investigators in Cancer Research to study melanoma. Dr. Simon is the Fernholz Foundation Research Scholar in Neuroscience and an a
- FDA Greenlights Phio Pharmaceuticals' Trial of PH-762 in Skin Cancerhttps://practicaldermatology.com/news/fda-greenlights-phio-pharmaceuticals-trial-of-ph-762-in-skin-cancer/2461721/The U.S. Food and Drug Administration (FDA) has cleared Phio Pharmaceuticals’ Investigational New Drug (IND) application to move ahead with a clinical trial of PH-762 for treating skin cancer. PH-762 is an INTASYL compound
- First Subject Dosed in Phase 1 Clinical Study of NM26 for ADhttps://practicaldermatology.com/news/first-subject-dosed-in-phase-1-clinical-study-of-nm26-for-ad/2461718/The first subject has been dosed in the Phase 1 clinical study of Numab Therapeutics’ NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD). This marks the beginning of a combined single ascending dose (SAD) and multip
- Skinvive by Juvéderm Scores FDA Nod to Improve Skin Smoothness in Cheekshttps://practicaldermatology.com/news/skinvive-by-juvederm-scores-fda-nod-to-improve-skin-smoothness-in-cheeks/2461717/The U.S. Food and Drug Administration gave its nod to Skinvive by Juvéderm to improve skin smoothness of the cheeks in adults over the age of 21. Skinvive by Juvéderm is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness availabl
- Mindfulness and Self-compassion Training Improve QOL for AD Patientshttps://practicaldermatology.com/news/mindfulness-and-self-compassion-training-improve-qol-for-ad-patients/2461713/Online group mindfulness and self-compassion training improves quality of life in adults with atopic dermatitis (AD). In this randomized clinical trial of 107 adults with AD, mindfulness and self-compassion training in addition to usual care showed significantly greater improvement
- Stony Brook University Hospital and The Mollie Biggane Melanoma Foundation Promote Skin Cancer Prevention Through New Inpatient Initiativehttps://practicaldermatology.com/news/stony-brook-university-hospital-and-the-mollie-biggane-melanoma-foundation-promote-skin-cancer-prevention-through-new-inpatient-initiative/2461709/Stony Brook University Hospital (SBUH) and the Mollie Biggane Melanoma Foundation announce a collaboration to provide Stony Brook patients with skin cancer education through their inpatient Electronic Medical Records program, according to a news release. Historicall
- American Academy of Dermatology Survey Shows Generation Z Adults are Unfamiliar with Sunburn and Tanning Riskshttps://practicaldermatology.com/news/american-academy-of-dermatology-survey-shows-generation-z-adults-are-unfamiliar-with-sunburn-and-tanning-risks/2461708/A recent American Academy of Dermatology survey of more than 1,000 US adults revealed that many Generation Z adults, ages 18-25, are unaware of the risks associated with overexposure to the sun and believe tanning myths, according to an AAD news release. According to the surv
- FDA Set to Review Ortho Derm's Triple Combo Acne Gelhttps://practicaldermatology.com/news/fda-set-to-review-ortho-derms-triple-combo-acne-gel/2461705/The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Ortho Dermatologics’ investigational IDP-126 (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) Gel. The Prescription Drug User Fee Act (PDUFA) action date is set for October 20, 2023, accordin